Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA '522' Guidance: 15-Month Deadline To Comply With Postmarket Order

This article was originally published in The Gray Sheet

Executive Summary

The agency has issued a final guidance on Sec. 522 postmarket study orders about five years after a draft version. In the interim, Congress stipulated a 15-month deadline for companies to start the FDA-mandated studies, a requirement emphasized in the new document.

Advertisement

Related Content

In Case You Missed It: Top 10 Gray Sheet Stories In May
Senate Seeks Performance Data From FDA On De Novos, Postmarket Surveillance
Warning Letter: Exoskeleton Firm Dodged Communication With FDA Over Postmarket Study, Failed To Assemble Surveillance Plan
Duodenoscope-Makers Ordered By FDA To Conduct Sec. 522 Postmarket Surveillance Studies
Metal-On-Metal Hip Post-market Studies Behind Schedule, NEJM Article Highlights
FDA Emphasizes Efficiency In 522 Surveillance Order Draft Guidance

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT034792

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel